ImmunoCellular Therapeutics Announces Initiation of Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma
Last July-Aug it hit about $4, so that could be some significant resistance after $3.6-we'll see.
Analyst Ratings for ImmunoCellular Therapeutics (IMUC)Average: $8.38
IMUC Rating Summary
Buys – 4
Neutrals – 0
Sells – 0
IMUC Price Target Summary Average: $8.38
Highest: $18.00 (Maxim Group)
Lowest: $4.50 (McNicoll Lewis & Vlak)
Research on IMUC
Overall Rating: BUY Rating Trend: Up Avg. $ Target: $8.38 (+159.3%)
Agree! If fact thought we were going past that number when we hit 3.40. But the pullback is good and offers hope we run thru 3.60. Good luck!
Sentiment: Strong Buy